PURPOSE Tumors from 50% of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer patients that develop resistance to gefitinib or erlotinib will contain a secondary EGFR T790M mutation. As most patients do not undergo repeated tumor biopsies we evaluated whether EGFR T790M could be detected using plasma DNA. EXPERIMENTAL DESIGN DNA from plasma of 54 patients with known cli...

PURPOSE The purpose of this study was to explore the frequencies of ALK and ROS1 fusion genes in EGFR-mutant lung adenocarcinoma patients and examine the therapeutic efficacies of EGFR-tyrosine kinase inhibitors (TKIs). MATERIALS AND METHODS A total of 421 EGFR-mutated patients taking EGFR-TKIs were examined for ALK and ROS1 fusion genes based on reverse transcription-polymerase chain reactio...

PURPOSE Epidermal growth factor receptor (EGFR) overexpression is associated with poor prognosis in head and neck squamous cell carcinoma (HNSCC). Despite intensive biomarker studies, a consensual method for assessing EGFR protein expression is still lacking. Here we set out to compare three EGFR detection methods in tumor specimens from HNSCC patients. EXPERIMENTAL DESIGN Tumors were prospec...

Epidermal growth factor receptor (EGFR) gene mutation and copy number are useful predictive markers that guide the selection of non-small cell lung cancer (NSCLC) patients for EGFR-targeting therapy. This study aimed to investigate the correlation between EGFR gene mutation and copy number and clinicopathologic characteristics of Chinese patients with NSCLC. NSCLC specimens collected from 205 p...

OBJECTIVE In this study, we investigated the predictive capacity of the brachial-ankle aortic pulse wave velocity (baPWV), a marker of arterial stiffness, for the decline in renal function and for cardiovascular events in the early stages of chronic kidney disease (CKD). METHOD Two hundred forty-one patients who underwent a comprehensive check-up were included and were divided into two groups...

PURPOSE The purpose of this study was to investigate the potential effect of activation of epidermal growth factor receptor (EGFR) signaling pathway on the expression of programmed death-ligand 1 (PD-L1) in esophageal squamous cell carcinoma (ESCC) cells with EGFR overexpression. METHODS Flow cytometry and Western blot methods were used to assess PD-L1 expression on ESCC cells when EGFR signa...

Purpose: Mutant selective irreversible pyrimidine-based EGFR kinase inhibitors, includingWZ4002,CO-1686, andAZD9291, are effective in preclinical models and in lung cancer patients harboring the EGFR T790Mgefitinib/erlotinib resistancemutation. However, little is known about how cancers develop acquired resistance to this class of EGFR inhibitors. We sought to identify and study EGFR mutations ...

BACKGROUND As up to 60 % of triple negative breast carcinomas are reported to express EGFR, the receptor is a potential target for biological therapy. The exact role EGFR plays in triple negative breast carcinoma (TNBC) biology, however, remains uncertain. We aimed to discover associations between EGFR protein expression as well as gene copy number changes and clinico-pathologic TNBC characteri...

Abstract EGFR mutation-positive patients with non–small cell lung cancer (NSCLC) respond well to treatment EGFR–tyrosine kinase inhibitors (EGFR–TKI); however, EGFR–TKIs is not curative, owing the presence of residual cells intrinsic or acquired resistance this class drugs. Additional targets that may enhance efficacy remain elusive. Using a CRISPR/Cas9-based screen, we identified leucine-rich ...

Background: The transformation of epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD) into small cell cancer (SCLC) accounts for 3–14% the resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs). At present, there is no relevant research explore dynamic expression EGFR-mutant proteins and genomic evolution in transformed SCLC/neuroendocrine carcinoma (NEC).